Biotech-stock investing has one tough test for success - and it's about to get easier ...
Wilson celebrates the first U.S. patient to complete gene therapy for sickle cell, but says advocacy must continue.
Skorney cited a drug called Oxbryta from Pfizer (PFE), which was approved to treat the blood disorder sickle cell. Instead of using clinical benefit as the benchmark, the FDA approved Oxbryta based on ...
High-yield dividend stocks have been gaining momentum ahead of potential Fed rate cuts. While sticky inflation and possible ...
Q3 2024 Earnings Call Transcript November 13, 2024 Operator: Good morning, and welcome to Fulcrum Therapeutics Third Quarter ...
It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.
Andrew Fein, an analyst from H.C. Wainwright, reiterated the Hold rating on Fulcrum Therapeutics (FULC – Research Report). The associated ...
Patient enrollment and site activation progressing in Phase 1b PIONEER trial of pociredir in sickle cell disease (SCD) ― ― Ended the third quarter of 2024 with $257.2 million in cash, cash equivalents ...
The social campaign aimed to defy stigma, give voice to patients and care providers and pave the way for the launch of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback